Cite
de Bono JS, Fleming MT, Wang JS, et al. Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clin Cancer Res. 2021;27(13):3602-3609doi: 10.1158/1078-0432.CCR-20-4528.
de Bono, J. S., Fleming, M. T., Wang, J. S., Cathomas, R., Miralles, M. S., Bothos, J., Hinrichs, M. J., Zhang, Q., He, P., Williams, M., Rosenbaum, A. I., Liang, M., Vashisht, K., Cho, S., Martinez, P., & Petrylak, D. P. (2021). Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3602-3609. https://doi.org/10.1158/1078-0432.CCR-20-4528
de Bono, Johann S, et al. "Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3602-3609. doi: https://doi.org/10.1158/1078-0432.CCR-20-4528
de Bono JS, Fleming MT, Wang JS, Cathomas R, Miralles MS, Bothos J, Hinrichs MJ, Zhang Q, He P, Williams M, Rosenbaum AI, Liang M, Vashisht K, Cho S, Martinez P, Petrylak DP. Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clin Cancer Res. 2021 Jul 01;27(13):3602-3609. doi: 10.1158/1078-0432.CCR-20-4528. Epub 2021 Apr 01. PMID: 33795255.
Copy
Download .nbib